Skip to main content

Significant investments

Typically, building a strategic position begins by investing in a private company with development potential and expands at follow-on financing rounds as well as IPOs.

HBM Healthcare is committed to broad diversification according to the following parameters: private and public companies; development phase; therapeutic area; geography; company size (market capitalisation, valuation). Without the Board of Directors' approval, the acquisition value of an investment may not exceed 10 percent of net assets.

Overview as at 30 September 2024

CHF
204
million
Shanghai Cathay Biotech
Swixx BioPharma
CHF
201
million
CHF
73
million
Harmony Biosciences
Neurelis
CHF
48
million
CHF
45
million
Fangzhou (Jianke)
Upstream Bio
CHF
37
million
Y-mAbs Therapeutics
CHF
37
million